Salivary excretion of mexiletine after bolus intravenous administration in rats

Abstract— Salivary excretion of mexiletine was investigated following bolus intravenous administration (10 mg kg−1) in rats. Parotid and mandibular saliva was collected separately by stimulating salivation with constant rate infusion of pilocarpine (3 mg kg−1 h−1). The mexiletine levels in blood plasma and parotid and mandibular saliva declined biexponentially with time in almost parallel fashion. Although the mexiletine levels in both types of saliva were lower than that in plasma, the drug level in parotid saliva was always higher than that in mandibular saliva. Significant correlations were observed when all data relating mexiletine concentration in plasma and saliva were included (P < 0·001). The saliva/plasma drug concentration ratios (S/P ratios) did not vary to a large extent (0·56 ± 0·10 for parotid saliva, 0·21 ± 0·06 for mandibular saliva), but there was a consistent tendency for the higher plasma drug levels in the distribution phase to produce relatively high S/P ratios for both parotid and mandibular saliva. Moreover, the plasma mexiletine levels calculated by the equation of Matin et al (1974) employing the observed values for the saliva drug level, saliva pH and free fraction of mexiletine in plasma were significantly higher than the observed drug levels. Therefore, it is suggested that the salivary excretion of mexiletine could not be explained quantitatively by simple, passive secretion based on pH‐partition theory.

[1]  Y. Hayashi,et al.  Mandibular and Parotid Salivary Levels of Indomethacin Following Intravenous Administration to Rabbits , 1985, Pharmaceutical Research.

[2]  M. Hayashibara,et al.  Salivary excretion of mexiletine in normal healthy volunteers , 1991, The Journal of pharmacy and pharmacology.

[3]  M. Hayashibara,et al.  Comparison of Saliva Stimulation Methods for Noninvasive Therapeutic Drug Monitoring by Using Saliva Samples , 1989 .

[4]  Y. Hayashi,et al.  Salivary excretion of 5-fluorouracil (5-FU). IV. Dependency of saliva/plasma concentration ratio and salivary clearance on plasma concentration of 5-FU during constant-rate intravenous infusion in rats. , 1989, Journal of pharmacobio-dynamics.

[5]  Y. Hayashi,et al.  Salivary excretion of 5-fluorouracil (5-FU). III. Non-linear kinetics of salivary excretion of 5-FU following bolus intravenous administration in rats. , 1988, Chemical & pharmaceutical bulletin.

[6]  Y. Kanai,et al.  Effect of perfused rat mandibular-gland pHI on the ratio of procainamide concentration in saliva to that in venous effluent. , 1988, Biochemical pharmacology.

[7]  K. Iwamoto,et al.  Mandibular and parotid salivary excretion of procainamide and N‐acetylprocainamide after intravenous administration of procainamide to rats , 1987, The Journal of pharmacy and pharmacology.

[8]  Y. Hayashi,et al.  Salivary excretion of 5-fluorouracil. I. Fluctuation of the saliva/plasma concentration ratio and salivary clearance in beagle dogs following bolus intravenous administration. , 1985, Chemical & pharmaceutical bulletin.

[9]  J. Turgeon,et al.  High pressure liquid chromatographic assay for mexiletine in serum. , 1984, Journal of chromatographic science.

[10]  Y. Hayashi,et al.  Protein binding effects of salivary excretion of phenobarbital in dogs. , 1981, Journal of pharmacobio-dynamics.

[11]  Y. Nakase,et al.  Excretion of indomethacin into saliva following intravenous administration to dogs. , 1981, Journal of pharmacobio-dynamics.

[12]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[13]  M. Danhof,et al.  Therapeutic Drug Monitoring in Saliva , 1978, Clinical pharmacokinetics.

[14]  J. E. Rees Biopharmaceutical implications of compaction and consolidation in the design of drug dosage forms. , 1978, Bollettino chimico farmaceutico.

[15]  P Kellaway,et al.  Use of saliva in therapeutic drug monitoring. , 1977, Clinical chemistry.

[16]  Beckett Ah,et al.  The distribution, metabolism and excretion of mexiletine in man. , 1977 .

[17]  A. Beckett,et al.  The distribution, metabolism and excretion of mexiletine in man. , 1977, Postgraduate medical journal.

[18]  L B Sheiner,et al.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide , 1976, Clinical pharmacology and therapeutics.

[19]  B. Dvorchik,et al.  Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. , 1976, Clinical chemistry.

[20]  J. Karam,et al.  Pharmacokinetics of tolbutamide: Prediction by concentration in saliva , 1974, Clinical pharmacology and therapeutics.

[21]  D. Julian,et al.  Treatment of ventricular arrhythmias with mexiletine (Kö 1173). , 1973, Lancet.